Alfimeprase
- Generic Name
- Alfimeprase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 259074-76-5
- Unique Ingredient Identifier
- GPN9HBH1HS
- Background
Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (Agkistrodon contortrix contortrix). It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.
- Indication
Alfimeprase is being evaluated as a potential treatment for acute ischemic stroke, catheter occlusion (CO) and acute peripheral arterial occlusion (PAO).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00499902
- Locations
- ๐จ๐ฆ
University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada
๐จ๐ฆVancouver General Hospital, Vancouver, British Columbia, Canada
๐จ๐ฆMontreal Neurological Institute, Montreal, Quebec, Canada
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
- Conditions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00346424
- Locations
- ๐บ๐ธ
Corvallis Clinic, Corvallis, Oregon, United States
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00338585
- Locations
- ๐บ๐ธ
Montefiore Medical Center, Bronx, New York, United States
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
- Conditions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2008-08-15
- Lead Sponsor
- ARCA Biopharma, Inc.
- Registration Number
- NCT00322270
- Locations
- ๐บ๐ธ
Mercy Hospital, Miami, Florida, United States
๐บ๐ธHematology/Oncology Consultants, Inc., Columbus, Ohio, United States
๐บ๐ธCancer Research & Prevention Center, Soquel, California, United States
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
- Conditions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00115999
- Locations
- ๐บ๐ธ
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
- Conditions
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2009-12-17
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00073554
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
- Conditions
- First Posted Date
- 2003-11-25
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT00073515
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.